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Abstract
Recently, neurotrophic factors and cytokines have been shown to be associated in psychiatric disorders, such as
schizophrenia, bipolar disorder, and depression. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a
member of the EGF family, serves as a neurotrophic molecular and plays a significant role in the brain. We generated mice in
which HB-EGF activity is disrupted specifically in the ventral forebrain. These knockout mice showed (a) behavioral
abnormalities similar to those described in psychiatric disorders, which were ameliorated by typical or atypical
antipsychotics, (b) altered dopamine and serotonin levels in the brain, (c) decreases in spine density in neurons of the
prefrontal cortex, (d) reductions in the protein levels of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor and
post-synaptic protein-95 (PSD-95), (e) decreases in the EGF receptor, and in the calcium/calmodulin-dependent protein
kinase II (CaMK II) signal cascade. These results suggest the alterations affecting HB-EGF signaling could comprise a
contributing factor in psychiatric disorder.
Citation: Oyagi A, Oida Y, Kakefuda K, Shimazawa M, Shioda N, et al. (2009) Generation and Characterization of Conditional Heparin-Binding EGF-Like Growth
Factor Knockout Mice. PLoS ONE 4(10): e7461. doi:10.1371/journal.pone.0007461
Editor: Rafael Linden, Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Biofı ´sica da UFRJ, Brazil
Received June 26, 2009; Accepted September 15, 2009; Published October 14, 2009
Copyright:  2009 Oyagi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by the Gifu pharmaceutical University. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Competing Interests: K. Yamaguchi is an employee of Nihon Bioresearch Center Inc. The other authors declare no competing interests exist.
* E-mail: hidehara@gifu-pu.ac.jp
Introduction
Heparin-binding epidermal growth factor-like growth factor
(HB-EGF) is a member of the EGF family of growth factors that
includes EGF, transforming growth factor (TGF)-a, amphiregulin,
betacelulin, and neuregulin [1,2,3]. HB-EGF binds to and
activates the EGF receptor (EGF receptor/ErbB1) [1], ErbB4
[4], heparan sulfate proteoglycan (HSPG) [5], and N-arginine of
dibasic convertase (NRDc) [6]. In the brain, EGF family members
act as neurotrophic molecules, serving to enhance stem cell
proliferation and neural differentiation, and they also influence
synaptic plasticity [7,8,9]. HB-EGF is highly enriched in the
neocortex and cerebellum [10,11] and has been implicated in
neuronal survival and glial/stem cell proliferation [12,13,14].
Recent studies indicate that this growth factor contributes to
neurogenesis in the subventricular zone and adult hippocampus,
thus maintaining multipotent neural progenitor cells expressing
the ErbB1 receptor [13,15]. HB-EGF also promotes the survival of
dopaminergic neurons, an action mediated by mitogen-activated
protein kinase (MAPK) as well as by the Akt signaling pathway
[14]. For these reasons, HB-EGF may be an important contributor
to neural development.
Abnormal development of the brain is implicated in the etiology
and/or pathology of various psychiatric diseases, including
schizophrenia [16], bipolar disorder [17], and depression [18],
among others. Similarly, psychiatric patients can display abnor-
malities in the expression of cytokines and neurotrophic factors.
For instance, the levels of brain-derived neurotrophic factor
(BDNF) expression are specifically elevated in the hippocampus
and cingulated cortex of schizophrenic patient, while conversely,
its receptor, trkB protein, is reduced in the prefrontal cortex and
hippocampus of them [19]. EGF protein levels have been found to
be lower in the prefrontal cortex and striatum of schizophrenic
patients [20]. Serum EGF levels were also lower in these patients,
whereas EGF receptor expression in the prefrontal cortex was
elevated [20]. All of these findings indicate that the EGF signal
cascade may contribute to the pathology of a number of
psychiatric diseases. On the other hand, since peptides other than
authentic EGF (e.g., TGF-a and HB-EGF) are expressed at much
higher levels than EGF itself [11], it is possible that HB-EGF
serves as a major physiologic ligand for the EGF receptor within
the central nervous system.
At the present time, little is known about the relationship
between HB-EGF and psychiatric disorders. In the current study,
therefore, we have generated HB-EGF conditional knockout (KO)
mice that exhibit disruption of HB-EGF activity specifically in the
ventral forebrain. We have compared the neurobehavioral and
molecular biological characteristics of these mice with those of
control mice and have demonstrated that the HB-EGF KO mice
exhibit behavioral and biological abnormalities similar to those
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7461described in various psychiatric disorders. These results strongly
suggest that alterations in HB-EGF signaling contribute to the
pathogenesis of mental illness.
Results
Generation of HB-EGF KO mice
Since a homozygous null mutation of the Hb-egf gene causes
lethality [21], in order to investigate the role of HB-EGF in the
(adult/postnatal) brain, we generated ventral forebrain specific
HB-EGF KO mice using a Cre-lox-mediated conditional gene
KO approach with Six3 promoter [22]. This strategy for
generating the HB-EGF KO mice, hereafter referred to as Cre
(+/2) HB (lox/lox), is shown in Fig. 1a. The resulting Cre (+/2)
HB (lox/lox) and control HB (lox/lox) mice were identified by
polymerase chain reaction (PCR) analysis (Fig. 1b). HB (lox/lox)
mice showed the same expression patterns for HB-EGF mRNA
and protein in various regions of the brain (hippocampus,
prefrontal cortex, cerebellum, and striatum) when compared with
wild-type C57BL/6J mice (data not shown). Additionally, we
confirmed the disruption of Hb-egf gene by lacZ staining. LacZ
positive cells were founded in the prefrontal cortex and
hippocampus in KO mice (Fig. 1d, and f). For a further
examination of the expression of Hb-egf mRNA and its protein
Figure 1. Generation of HB-EGF KO mice. (a) Gene-targeting strategy. Mouse Hb-egf cDNA containing the polyadenylation (pA) sequence
flanked by loxP sequences was fused with the first exon of the mouse Hb-egf gene. The lacZ gene was inserted downstream of the Hb-egf cDNA. The
targeting vector also contains the neomycin-resistance gene (neo), driven by the phosphoglycerate kinase (PGK) promoter and the diphtheria toxinA-
fragment (DT-A) gene. Cre-mediated recombination results in the deletion of Hb-egf cDNA and in the expression of the lacZ gene. Exon sequences are
indicated as black boxes. E, EcoR1; H, hind1; K, Kpnl; S, Sacll; V, EcoRV; X, Xhol. (b) Genotype of ventral forebrain-specific HB-EGF KO mice. Ventral
forebrain-specific HB-EGF-deficient mice were confirmed by PCR as lox homozygous and Cre-recombinase positive. (c) Coronal section through the
cortex region; square indicates area shown in the photomicrographs. (d) Histological analysis of cortex from controls (upper) and HB-EGF KO (lower)
adult mice. LacZ staining, scale bar=50 mm. In situ hybridization using an Hb-egf probe, scale bar=100 mm. Immunohistochemical staining with anti-
HB-EGF antibody, scale bar=20 mm. Cresyl violet staining, scale bar=500 mm. (e) Coronal section through the hippocampus; square indicates area
shown in the photomicrographs (CA1, CA3, and DG). (f) LacZ staining of whole and individual hippocampal region in HB-EGF KO mice, scale
bar=500 mm. (g) Immunohistochemical analysis of individual hippocampal region from controls (upper) and HB-EGF KO (lower) adult mice, scale
bar=20 mm.
doi:10.1371/journal.pone.0007461.g001
HB-EGF and Psychiatric Disease
PLoS ONE | www.plosone.org 2 October 2009 | Volume 4 | Issue 10 | e7461in HB-EGF KO and control mice, we performed in situ
hybridization analysis and immunohistrochemical analysis respec-
tively (Fig. 1d). In the prefrontal cortex, the expression of Hb-egf
mRNA and protein were found to be considerably reduced in KO
mice (Fig. 1d). Similarly, HB-EGF protein was undetectable
beyond the background level in the cell layer of CA1, CA3, and
dentate gyrus (DG) of KO mice hippocampus (Fig. 1g). However,
we could detect no significant differences in the weights of
individual brain regions (Table S1), and cresyl violet staining of
adult brain sections showed no difference in the lamination or
structure of cortical cells between HB-EGF KO mice and their
control littermates (Fig. 1d). There were no significant differences
in the body weight of adult KO or control mice. Mean body
weights of mice used for each experiment are as follows:
Locomotor activity and social interaction [Control; 27.060.51 g
(mean6S.E.M., n=25), KO; 26.660.52 g (n=22)], PPI [Control;
25.560.33 g (n=53), KO; 24.960.38 g (n=65)], Monoamine
analysis [Control; 25.260.69 g (n=11), KO; 25.860.73 g
(n=11)], Y-maze, Novel object recognition test, and Western
blotting [Control; 22.060.63 g (n=6), KO; 22.060.73 g (n=6)],
and Morphological analysis [Control; 22.460.59 g (n=5), KO;
21.660.74 g (n=5)].
HB-EGF KO mice exhibited abnormal psychomotor
behaviors
To investigate the involvement of HB-EGF in psychomotor
behaviors, we performed several types of neurobehavioral tests.
First, we studied the behavior of HB-EGF KO and control mice in
their cages to measure locomotor activity. HB-EGF KO and
control mice displayed a normal circadian rhythm (i.e., their
activity was reduced during the light phase [8 A.M. to 8 P.M.] and
then increased markedly at the beginning of the dark phase)
(Fig. 2a). However, HB-EGF KO mice were more active than
control mice over the 24-hr period (both dark and light phases)
(P,0.05 vs. control mice) (Fig. 2a and b). During the first 0–3 hr of
the test, HB-EGF KO mice were also more active than control
mice, indicating that HB-EGF KO mice are also hyperactive in a
novel environment. To test the involvement of dopaminergic and
serotonergic neuronal systems in the increased locomotor activity,
we examined the effects of a potent dopamine (DA) receptor
Figure 2. Behavioral analysis of HB-EGF KO mice and control mice. (a and b) Locomotor activity test. Mice were placed into individual cages,
and their locomotion was assessed every hour for 1 day. Controls (n=8), KO mice with treatment of vehicle (n=7), haloperidol (n=8), and clozapine
(n=8). (a) Locomotor activity throughout the 24-hr period, and (b) locomotor activity analyzed separately during day and night periods. (c) PPI of the
acoustic startle response in control (n=24), KO mice with treatment of vehicle (n=24), haloperidol (n=15), risperidone (n=14), and clozapine
(n=12). The PPI is expressed as a percentage of the startle response to a 120 dB pulse. (d) Social interaction test in a novel environment in controls
(n=8) and KO mice with treatment of vehicle (n=7), haloperidol (n=9), and clozapine (n=9). Two genetically identical mice that had been housed
separately were placed in the same cage. Their social interaction was then monitored for 10 min. Values are means6SEM. (e and f) Novel-object
recognition task. (e) In the training trial (5 min), two circles were placed in symmetrical left and right positions. (f) In the test trial 1 hr later (5 min),
one circle (left) and one triangle (right) were placed in the same positions. The amount of time the control (n=6) and KO (n=6) mice spent exploring
each object during training trial and test trial was recorded. * p,0.05 vs. left object. (g and h) Y-maze task. Each mouse was placed at the end of one
fixed arm of the maze and allowed to move freely through the maze for 8 min. The sequence of arm entries was recorded manually. (g) Total number
of arms entered during the session. (h) % of alternation was calculated as (actual alternations/maximum alternations)6100. Control (n=6), KO (n=6).
Values are means6SEM. * p,0.05 vs. control mice. #p,0.05, ##p,0.01 vs. vehicle-treated HB-EGF KO mice.
doi:10.1371/journal.pone.0007461.g002
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antagonist, risperidone and clozapine, in HB-EGF KO mice.
Haloperidol (0.1 mg/kg, i.p.) ameliorated the hyperlocomotion of
HB-EGF KO mice both in dark and light phases (P,0.05 vs.
vehicle-treated HB-EGF KO mice in each phases). On the other
hand, clozapine reduced the locomotor activity of HB-EGF KO
mice only in light phase. Furthermore these drugs did not
attenuate locomotor activity in control mice at each dose (Table
S2).
To investigate the possible role of HB-EGF in sensorimotor
gating, prepulse inhibition (PPI) was measured in HB-EGF KO
and control mice. Sensorimotor gating is the neural process in
which allow attention to be focused on one stimulus. Sensorimotor
gating can be assessed as PPI of startle, which is the modulation of
the startle response, following a weak prepulse. In the pulse-only
trials, startle amplitude did not differ significantly between HB-
EGF KO and control mice, [Control; 263.7633.56 (mean6
S.E.M, n=25), KO-vehicle; 205.8635.25 (n=24), KO-haloper-
idol; 230.2660.6 (n=15), KO-risperidone; 212.5643.78 (n=14),
and KO-clozapine; 225.2635.03 (n=12)]. HB-EGF KO mice
showed diminished PPI at prepulse intensities of both 73 and 76
dB (P,0.05 vs. control mice) (Fig. 2c). Moreover, PPI deficit
observed in HB-EGF KO mice were significantly reversed by
atypical antipsychotics, risperidone and clozapine (P,0.05 vs.
vehicle-treated HB-EGF KO mice), but not by a typical
neuroleptic haloperidol (P.0.05). These drugs did not affect PPI
in control mice at each dose (Table S2).
To assess the social affiliative behavior of HB-EGF KO mice,
we employed a social interaction paradigm. When introduced to
another mouse, a normal mouse will typically investigate the new
mouse by walking over and sniffing it. But animal models of
psychiatric disorders tend to show decreases in such social-
interaction behavior. During a 10 min social interaction test in a
novel environment, the mean duration per contact was signifi-
cantly less in HB-EGF KO mice than in control mice, indicating
that HB-EGF KO mice spent significantly less time engaging in
social contact (P,0.05 vs. control mice) (Fig. 2d). We could not
detect any differences in olfactory sensation between either
genotype (data not shown). Mice were pretreated with haloperidol
or clozapine for 7 days and subjected to the social interaction test.
Clozapine, but not haloperidol, significantly attenuated the
decreased social interaction behavior of HB-EGF KO mice
(P,0.05 vs. vehicle-treated HB-EGF KO mice) (Fig. 2d). During a
10 min social interaction test, not only the mean duration per
contact but also the time of interaction were significantly less in
HB-EGF KO mice than in control mice [Control; 41.763.37 sec
(mean6S.E.M, n=8), KO-vehicle; 27.165.13* sec (n=7), KO-
haloperidol; 21.062.68 (n=9), KO-clozapine; 24.762.44 (n=9),
*p,0.05 vs. control mice]. On the other hand, no significant
changes were observed in the number of interactions between HB-
EGF KO and Control mice [Control; 20.461.31 counts (mean6
S.E.M, n=8), KO-vehicle; 18.462.72 counts (n=7), KO-
haloperidol; 14.761.86 (n=9), KO-clozapine; 13.261.31
(n=9)]. Furthermore these drugs did not affect the social
interaction in control mice at each dose (Table S2).
Using a novel-object recognition test, we next investigated the
effect of deletion of the Hb-egf gene on learning and memory
performance. The exploratory behavior of the HB-EGF KO mice
and control mice did not differ during the training session (P.0.05
vs. control mice) (Fig. 2e). However, in the test trials conducted
1 hr after the training session, control mice spent significantly
more time exploring a new object than a familiar object, exhibiting
a clear preference for the novel object (P,0.05 vs. control mice)
(Fig. 2f). In contrast, HB-EGF KO mice spent equal amounts of
time investigating the novel object and the familiar object (P.0.05
vs. control mice) (Fig. 2f).
Next, to further assess the specificity of changes in working
memory related to the loss of HB-EGF protein, we elected to test
spontaneous alternation in the Y-maze, which is devoid of any
procedural bias because it is based on the natural tendency of mice
to explore a novel environment. There was no difference in the
number of arm choices or in preference for a particular arm
between HB-EGF KO and control mice (Fig. 2g). However, HB-
EGF KO mice displayed a significant decrease in alternation
compared to control mice (P,0.05 vs. control mice) (Fig. 2h).
Changes in monoamine levels
It is commonly believed that behavioral abnormalities are
associated with alterations in monoaminergic transmission [23].
To investigate whether targeted disruption of the Hb-egf gene
affected the function of monoaminergic neuronal systems, tissue
levels of monoamines and their metabolites were assessed in various
regions of the brain in HB-EGF KO and control mice. In the
prefrontal cortex, DA, 5-HT, and its metabolite 5-hydroxyindole
acetic acid (5-HIAA) levels were statistically lower in HB-EGF KO
micethan incontrolmice (P,0.05vs.controlmice) (Fig. 3a). The 5-
HT level in the thalamus and the DA levels in the cerebellum were
also lower in HB-EGF KO mice than in control mice (P,0.05 vs.
control mice) (Fig. 3b and c). In contrast, the striatal norepinephrine
(NE), its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG),
and 5-HT levels were higher in HB-EGF KO mice than in control
mice (P,0.05 vs. control mice) (Fig. 3d). On the other hand, no
significant differences in monoamine metabolites in various regions
of the brain (prefrontal cortex, thalamus, cerebellum, and striatum)
were observed between HB-EGF KO and control mice (Figure S1).
Morphological changes in the prefrontal cortex
To try to identify possible morphological correlates of the observed
abnormalities of behavior and cognition, we analyzed the morphol-
ogy of pyramidal neurons in cortical layer III in the prefrontal cortex.
Fig. 4a–c shows the morphology of such neurons in control (left) and
HB-EGF KO (right) mice. In these neurons, (I) there was no
significant difference in the number of basal dendritic branch-points
between controls and HB-EGF KO mice (P.0.05 vs. control mice)
(Fig. 4a and e); (II) as regards spine density in primary apical
dendrites, the number of spines per 10 mm of dendritic segment was
lower in KO than in control mice (P,0.0001 vs. control mice)
(Fig. 4b, c, and f); (III) there was no significant difference in dendrite
length between adult controls and KO mice (P.0.05 vs. control
mice)(Fig. 4g);and (IV) as regards the cumulativedistributionofspine
length, there was no significant difference between adult controls and
KO mice (P.0.05 vs. control mice) (Fig. 4h).
Next, we assessed by western blotting the protein levels of NR1
and PSD-95 as the obligatory subunits of the NMDA receptor and
its interacting molecule, which are thought to be involved in the
pathophysiology of schizophrenia. Fig. 4d shows immunoreactive
bands for NR1 and PSD-95. Both NR1 and PSD-95 were
markedly reduced in the prefrontal cortex of HB-EGF KO mice
(P,0.01 vs. control mice) (Fig. 4d, i, and j). In contrast, no
significant differences were observed in the expression of NR2A
and total NR2B proteins between controls and HB-EGF KO mice
(P.0.05 vs. control mice) (Fig. 4k and l).
Dysfunction of CaMKII and its related signals in HB-EGF
KO mice
By using western blotting, we next evaluated the protein levels
of total CaMKII a and b, phosphorylated CaMKII (p-CaMKII) a
HB-EGF and Psychiatric Disease
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serine-threonine kinases that regulate the synaptic architecture in
neurons. Fig. 5a and c show immunoreactive bands for total
CaMKII and p-CaMKII, respectively. P-CaMKII (a and b) was
markedly reduced in the prefrontal cortex of HB-EGF KO mice
(P,0.01 vs. control mice) (Fig. 5d), despite the presence of a
normal level of total CaMKII protein (Fig. 5b). Likewise, protein
levels of p-PAK1/3 and p-PAK2 were significantly lower in the
prefrontal cortex in HB-EGF KO mice than in control mice
(P,0.01 vs. control mice) (Fig. 5e and f).
Expression of the EGF receptor and its signals
To investigate the mechanisms that might lead to the observed
behavioral abnormalities and altered monoamine levels, we
compared the expression of the EGF receptor and its signaling
in HB-EGF KO and control mice. No significant differences in the
expression of total EGF receptor or ErbB4 proteins were observed
between controls and HB-EGF KO mice (P.0.05 vs. control
mice) (Fig. 6a and b). Despite these equivalent levels of EGF
receptor expression, p-EGF receptor protein was significantly
decreased in the prefrontal cortex of HB-EGF KO mice (P,0.05
vs. control mice) (Fig. 6c). Moreover, the expression of
phosphorylated extracellular signal-regulated kinase (p-ERK)
protein was significantly decreased in the prefrontal cortex of
HB-EGF KO mice (P,0.05 vs. control mice), despite comparable
levels of total ERK expression (Fig. 6d). No significant differences
in the expression of phosphorylated and total Akt or ErbB4
proteins were observed between controls and HB-EGF KO mice
(P.0.05 vs. control mice) (Fig. 6e and f). On the other hand, we
did not detect significant differences between controls and KO
mice regarding the relative expression of other EGF family growth
factors, such as EGF [Control; 10064.58 (mean6S.E.M., n=10),
KO; 10466.94 (n=10)], TGF-a [Control; 100611.8 (n=10),
KO; 10469.36 (n=10)], and betacelulin [Control; 10066.59
(n=10), KO; 99.666.48 (n=10)], using real-time PCR. No Real-
time PCR activity for epiregulin mRNA was observed under our
experimental conditions in either HB-EGF KO or control mice.
Discussion
In this study, we generated conditional HB-EGF KO mice using
a Cre/loxP system and were able to confirm the disruption of HB-
EGF in the prefrontal cortex and hippocampus of KO mice.
These results corresponded with a previous report which detected
the Six3 expression in the ventral forebrain and basal ganglion
[24]. Despite the decreased expression HB-EGF, the overall
development of HB-EGF KO mice appeared to be normal and
there were no significant differences in the body weight in the
adult KO or control mice. We also detected no significant
Figure 3. Tissue monoamine levels of individual brain regions. Levels of monoamine neurotransmitters and their major metabolites were
assayed in the (a) prefrontal cortex, (b) thalamus, (c) cerebellum, and (d) striatum of controls (n=11) and HB-EGF KO (n=11) mice. Values are
means6SEM. * p,0.05, ** p,0.01 vs. control mice. NE: Norepinephrine, MHPG: 3-methoxy 4-hydroxy phenethyleneglycol, DA: Dopamine, DOPAC:
3,4-dihydroxyphenilacetic acid, 3-MT: 3-methoxytyramine, HVA: homovanillic acid, 5-HT: Serotonin, 5-HIAA: 5-hydroxyindol acetic acid.
doi:10.1371/journal.pone.0007461.g003
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brain sections showed no difference in the lamination or structure
of cortical cells when investigated in either HB-EGF KO mice or
their control littermates.
To investigate the roles of HB-EGF in psychomotor behavior,
we performed a comprehensive behavioral analysis of ventral
forebrain-specific HB-EGF KO mice. Deficiencies in PPI and
memory tasks are considered to be signs of cognitive dysfunction
[25], whereas social withdrawal is one of the most disabling
symptoms in psychiatric disorders such as depression and
schizophrenia [26]. Hyperactivity is a characteristic of the rodent
models of several psychiatric disorders, such as schizophrenia [27]
and attention deficit hyperactivity disorder (ADHD) [28] and
could correspond to psychomotor agitation observed in human
patients with these disorders. The behavioral impairments
observed in HB-EGF KO mice were similar to those observed
in mice with treatment of NMDA receptor antagonists such as
phencyclidine (PCP) [29,30,31]. Consistent with these reports, in
the present studies, treatments with either a typical or an atypical
antipsychotic drug ameliorated these behavioral impairments in
KO mice. A typical antipsychotic (haloperidol) reduced the
locomotor activity of KO mice, but not the social withdrawal or
the deficit of PPI. In contrast, atypical antipsychotics (clozapine
and risperidone) ameliorated the impairments of social interaction
and PPI.
HB-EGF KO mice also displayed deficit of memory related
behavior, as observed by the Y-maze test performance and novel-
object recognition test. These deficits are considered to be signs of
cognitive and working memory dysfunction, respectively [32,33].
Taken together, the results from the present study indicate that
HB-EGF KO mice present with a comprehensive spectrum of
psychomotor and cognitive dysfunctions, all of which are
characteristic of rodent models of psychiatric disorders, such as
schizophrenia.
In general, abnormal behaviors are accompanied by altered
monoamine levels in animal models of psychiatric disorders [23].
Contrary to the classical DA hypothesis, which proposes that
hyperactivity of DA transmission is responsible for schizophrenia
[34], the DA level was statistically lower in the prefrontal cortex of
the HB-EGF KO mice than in the control mice. However, a
Figure 4. Morphological changes in the prefrontal cortex. (a) Representative photomicrographs showing morphology of pyramidal neurons
in cortical layer III of the prefrontal cortex from control (left) and KO (right) mice. Scale bar=20 mm. (b) Representative photomicrographs of apical
dendritic segments from control (left) and KO (right) mice. Scale bar=8 mm. (c) High-magnification images of apical dendritic segments from adult
control (left) and KO (right) mice. Scale bar=2 mm. (d) Representative images of immunoblots showing NR1 and PSD-95 protein levels. (e)
Quantification of the number of basal dendritic branch-points. (f) Spine density on primary apical dendrites of layer III pyramidal neurons of the
prefrontal cortex from control (white bar) and KO (black bar) mice. (g) Quantification of spine length. Control (n=700 spines) and KO (n=592 spines)
mice (n=4 mice, 25 neurons each). (h) Cumulative distribution of spine length. Control (white circle) and KO (black circle) mice (n=4 mice, 25
neurons each). (i, j, k, and l) Quantitative analysis of NR1, PSD-95, NR2A, and NR2B by densitometric scanning of immunoreactive bands. Control
(n=5), KO (n=5). Data for control and KO mice are expressed as a percentage of the control value. Values are means6SEM. ** p,0.01, *** p,0.001
vs. control mice.
doi:10.1371/journal.pone.0007461.g004
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DA level in the prefrontal cortex [35]. HB-EGF is known to
promote the survival of midbrain dopaminergic neurons [14];
therefore, the absence of an Hb-egf gene might be expected to
result in hypoplasia and hypofunction of dopaminergenic neurons.
On the other hand, the upregulation of NE, 5-HT, and its
metabolites observed in the striatum of the KO mice in the present
study may compensate for the downregulation of the prefrontal
monoamine levels.
The presence of NMDA receptor hypofunction in psychiatric
disorder has been inferred recently from a large number of clinical
and preclinical observations [36]. Genetic experiments in animals
suggest that the NR1 subunit, an essential part of the NMDA
receptor, plays an important role in cognitive function [37,38]. In
the present study, NR1 protein was markedly reduced in the
prefrontal cortex of HB-EGF KO mice. Malfunctioning NMDA
receptor signaling in the prefrontal cortex of KO mice may lead to
dysfunction in this brain region, perhaps resulting in the
impairments of recognition and spatial working memory that
were observed in this study.
The most significant finding made in the present study was that
the HB-EGF KO mice had a significantly decreased spine density
onthe primaryapicaldendritesofthelayerIIIpyramidalneuronsof
the prefrontal cortex (vs. control mice) of approximately 40%. Since
the dendritic spine is the major site of excitatory synaptic
transmission in the central nervous system, the size and density of
these spines will clearly influence the operation of functional circuits
[39,40,41]. In schizophrenic patients, spine density of these neurons
is decreased compared with normal controls [42]. The KO mice
also showed decreased expression of the NR1, PSD-95, p-CaMKII,
and PAK families, and these signaling pathways are known to
regulate synaptic structure and function in the developing cortex
[43,44,45]. Thus, the morphological changes observed in dendritic
spines may have been a result of the observed decreases in the
expression of the NR1, PSD-95, p-CaMKII, and PAK families.
These in turn may have led to the abnormalities in behavior and
monoamine levels seen in the KO mice.
Additionally, current evidence indicates that cytokines and
growth factors can strongly influence neural phenotypic differen-
tiation and subsequent neural function. Some studies have
indicated a potential link between impaired EGF signaling and
the pathogenesis of schizophrenia [20,46]. The EGF receptor is
expressed ubiquitously in both the developing and the adult brain
[47,48]. However, since peptides other than authentic EGF (e.g.,
TGF-a and HB-EGF) are expressed at much higher levels than
EGF itself [11], HB-EGF itself could be serving as a major
physiologic ligand for EGF receptor within the central nervous
system. In the present study, we detected a decrease in p-EGF
receptor protein and subsequent activation of ERK signaling in
the prefrontal cortex of HB-EGF KO mice (vs. control mice).
Figure 5. Activation of CaMKII and its related signals in HB-EGF KO and control mice. Representative images of immunoblotting showing
total CaMKII (a), p-CaMKII (c), p-PAK1/3, and p-PAK2 (e). Quantitative analysis of total CaMKII (b), p-CaMKII (d), p-PAK1/3, and p-PAK2 (f)b y
densitometric scanning of immunoreactive bands. Data for control (n=5) and KO (n=5) mice are expressed as a percentage of the control value.
Values are means6SEM. * p,0.05 vs. control mice.
doi:10.1371/journal.pone.0007461.g005
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mice with loxP-flanked Hb-egf cDNA) demonstrated that a
mutation of the Hb-egf gene was associated with decreases in the
activation of EGF receptor and ERK [49].
MAPKs, also known as ERKs, operate in a signaling cascade that
regulates various cellular processes (such as proliferation, differentia-
tion, and cell cycle progression). ERKs are recognized as being
important signaling components in learning and memory and in
regulating dendritic spine density [50]. Current evidence indicates that
continued exposure to clozapine stimulates p-ERKs, mediated by the
EGF receptor [51]. Down-regulation of EGF receptor signaling,
induced by mutation of the Hb-egf gene, could affect synaptic plasticity
by regulating NDMA relating proteins, and this would lead to the
abnormal behaviors observed in HB-EGF KO mice.
In conclusion, the current study demonstrates that HB-EGF KO
mice exhibited the behavioral abnormalities reflected in a
comprehensive spectrum of psychomotor and cognitive dysfunc-
tions, similar to many psychiatric disorders. Based on the
observations from the current study, we proposed a role for HB-
EGF in determining monoaminergic neural system and synaptic
plasticity. Many psychiatric disorders are multifactorial, reflecting
longitudinal and complex interactions of causative agents, including
genetic and environmental factors. These findings indicate that the
HB-EGF signaling may play a pivotal role in the pathogenesis of a
number of psychiatric disorders, including schizophrenia.
Materials and Methods
Generation of HB-EGF KO mice using a gene targeting
Cre-loxP and PCR
The targeting strategy has been described previously [21]. The
targeting construct is depicted in Fig. 1a. A 7.0-kb EcoRI–SacII
Figure 6. Expression of EGF receptor and its signals in HB-EGF KO and control mice. Representative images of immunoblots showing EGF
receptor and b-actin (a), ErbB4 and b-actin (b), p-EGF receptor and total EGF receptor (c), p-ERK, ERK, and b-actin (d), p-Akt, Akt, and b-actin (e), and
p-ErbB4 and ErbB4 (f) in the prefrontal cortex (upper). Quantitative analysis of EGF receptor (a), ErbB4 (b), p-EGF receptor (c), p-ERK (d), p-Akt (e), and
p-ErbB4 (f) by densitometric scanning of immunoreactive bands, with normalization to the signals for b-actin (a and b), EGF receptor (c), ERK (d), Akt
(e), or ErbB4 (f) (lower). Data for control (n=5) and KO (n=5) mice are expressed as a percentage of the control value. Values are means6SEM.
*p ,0.05 vs. control mice.
doi:10.1371/journal.pone.0007461.g006
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HindIII fragment from intron 3, and a 6.0-kb EcoRV fragment
downstream of the exon 4 were used as homology arms. Mouse
HB-EGF cDNA and a poly (A) signal flanked by loxP were fused
at exon 1. A 4.0-kb HindIII–XhoI fragment containing the loxP-
lacZ gene-poly (A) signal was inserted downstream of the HB-EGF
cDNA. A neo cassette driven by the phosphoglycerate kinase
promoter was inserted between the 1.3-kb intron 3 EcoRI–
HindIII fragment and the 6.0-kb EcoRV fragment downstream of
exon 4. XhoI-linearized DNA of the targeting vector was
electroporated into TT2 embryonic stem (ES) cells. Individual
clones were screened for homologous recombination by Southern
blot analysis of HindIII-digested DNA, corresponding to sequenc-
es that flank the targeting vector 59- and 39-arm used in the
screening of the HBlox allele. The targeted ES clones were
injected into ICR blastocysts, and the resulting chimeric mice were
bred with C57BL/6J female mice to obtain HB (lox/wt) mice.
Homozygous HB (lox/lox) mice were then obtained by inter-
breeding the HB (lox/wt) mice. Homozygous HB (lox/lox) mice
(C57BL/6J) were bred with Six3 promoter driven by Cre-
recombinase transgenic mice (C57BL/6-) [22] to generate Six3-
Cre-HB (lox/wt) mice. Subsequently, Six3-Cre-HB (lox/wt) mice
were bred with HB (lox/lox) mice to generate Six3-Cre-HB (lox/
lox) mice (HB-EGF KO mice) and HB (lox/lox) mice (HB-EGF
control mice). The genotype of each mouse was confirmed by
PCR. The primers have been reported previously [21]. Amplifi-
cation was performed using a DNA thermal cycler (PERKIN
ELMER, Norwalk, CT, USA) for 35 cycles. A cycle profile
consisted of 30 sec at 94uC for denaturation and 30 sec at 53uC
for annealing and primer extension. In the present study, to
minimize the influence of different genetic backgrounds between
HB (lox/lox) mice (C57BL/6J) and Six3-Cre transgenic mice
(C57BL/6-), the generated Six3-Cre-HB (lox/wt) mice were
backcrossed onto C57BL/6J HB (lox/lox) mice for more than 8
generations. HB (lox/lox) mice (C57BL/6J) used for backcrossing
were maintained by inbred mating.
Histological analysis
Mice (male, 10–20 weeks old) were anesthetized with sodium
pentobarbital (nembutal, 50 mg/kg, i.p., Dainippon Pharmaceu-
tical, Osaka, Japan), and the brains were perfusion-fixed with 4%
paraformaldehyde (Wako Pure Chemical Industries, Osaka,
Japan) in 0.1 M phosphate-buffered saline (PBS) (pH 7.4). The
brains were removed from the mice after 20 min of perfusion
fixation at 4uC and then immersed in the same fixative solution.
Brain sections were equilibrated in 25% sucrose solution and
quickly frozen in Tissue-Tek O.C.T. (Sakura Finetek, Torrance,
CA, USA).
For lacZ staining, after fixation with 0.2% glutaraldehyde and
1% formalin, tissues were incubated with 5-bromo-4-chloro-3-
indoly-b-galactoside (X-Gal) (Active Motif, Carlsbad, CA, USA)
for 2 hr at 4uC. For immunohistochemical staining, frozen sections
were washed for 5 min in 0.01 M PBS and then treated with 0.3%
hydrogen peroxidase in 10% methanol. They were then washed
three times in 0.01 M PBS, followed by a 30 min pre-incubation
with 10% normal goat serum. They were then incubated with a
rat anti-HB-EGF antibody (1:200), including 0.3% triton X-100,
overnight at 4uC. After a 15 min rinse in changes of 0.01 M PBS,
the sections were incubated with a secondary antibody, Alexa 488-
conjugated goat anti-rat IgG (Molecular Probes, Carlsbad, CA,
USA). In situ hybridization analysis was performed using an
antisense DIG-labeled cRNA probe. DIG-labeled cRNA probes
corresponding to Hb-egf (NM_010415) nucleotide positions 546 to
665 were synthesized, in situ hybridization analysis was performed,
as previously reported [52], and frozen sections (10 mm thick) were
stained with cresyl violet (Sigma, St. Louis, MO, USA).
Behavioral tests
All mice (male, 10–15 weeks old) were housed in a room with a
12-hr light/dark cycle (light on at 8:00 a.m.) and had ad libitum
access to food and water. Behavioral tests were performed between
9:00 a.m. and 5:00 p.m., except for the 24-hr locomotor activity
test. All procedures relating to animal care and treatment
conformed to the Animal Care Guidelines of the Animal
Experiment Committee of Gifu Pharmaceutical University.
Locomotor activity test
To measure the locomotor activity, a mouse was placed in the
cage, [plastic cage (17562456125 mm), wood-chips, food, and
water]. Locomotion was measured every 1 hr for 1 day using
digital counter with infrared sensor (NS-ASS01; Neuroscience,
Inc, Tokyo, Japan). Animals were placed into the cages at 2:00
P.M. for a 24 period. The room light was on from 8:00 A.M. to
8:00 P.M. Vehicle (0.3% tartaric acid), clozapine (1.0 mg/kg, i.p.),
or haloperidol (0.1 mg/kg, i.p.) was administrated once a day for 9
days, and one day after the final injection, locomotor activity test
was started.
Prepulse inhibition (PPI) test
Acoustic startle responses were measured in a startle chamber
(SR-LAB; San Diego Instruments, San Diego, CA) using standard
methods described previously [53]. In the demonstration of PPI of
acoustic startle reflex, subjects were presented with a series of
discrete trials comprising a mixture of four types of trials. These
included pulse-alone trials, prepulse-plus-pulsetrials, prepulse-alone
trials, and trials in which no discrete stimulus, other than the
constant background noise, was presented. A reduction of startle
magnitude in prepulse-pulse-pulse trials relative to those in pulse-
alone trials constitutes PPI. The pulse stimulus employed was 120
dB in intensity and 40 msec in duration. Prepulse of various
intensities as employed: 73, 76, and 82 dB. The duration of prepulse
stimuli was 20 msec. The stimulus onset asynchrony of the prepulse
and pulse stimuli on prepulse-plus-pulse trial was 100 msec. A
session began with the animals being placed into the Plexiglas
enclosure. Clozapine (WAKO) was dissolved in 0.1N HCl in saline
and neutralized to pH 6–7 with 0.1N NaOH. Haloperidol
(WAKO) and risperidone (WAKO) were dissolved in distilled water
containing 0.3% tartaric acid. Vehicle (0.3% tartaric acid),
clozapine (1.0 mg/kg, i.p.) haloperidol (0.1 mg/kg, i.p.), and
risperidone (0.1 mg/kg, i.p.) were administrated 30 min before
the measurement of PPI. Mice were acclimatized to the apparatus
for 5 min before the first trial began. Subsequently the animals were
presented with 3 blocks of discrete test trials. Each block consisted of
one trial of each of the following trial types: pulse-alone, prepulse-
plus-pulse trials of each of the five levels of prepulse, prepulse-alone
of each of the five levels of prepulse, and no stimulus (ie background
alone). The interval between successive trials was variable with a
mean of 30 sec (ranging from 20 to 40 sec).
Social interaction test
The social interaction test in a novel environment was done in a
manner similar to published method [54]. Each mouse was housed
in a group of 5–6 animals of the same genotype per cage during
the test. Two mice of identical genotypes, which were previously
housed in different cages, were placed into a box together
(17562456125 mm) and allowed to explore freely for 10 min.
Social behavior was monitored by a video camera. The number
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measured. During the 10 min observation period, observers
monitored the following behaviors: social interaction, sniffing,
following, genital investigation, facing, and mounting. The score
was calculated as the mean duration per contact. Haloperidol
(0.1 mg/kg, i.p.) and clozapine (1.0 mg/kg, i.p.) were adminis-
trated once a day for 7 days, and one day after the final injection,
social interaction test was started.
Novel object recognition task
Mice were tested in a circular arena, 40 cm in diameter. All mice
were habituated in the apparatus (without objects) for 40 min per
day priorto the trainingsession.At the end of each trial, the animals
were removed from the arena and the arena was cleaned with 70%
ethanol solution and dried with paper toweling. Object recognition
was scored by the amount of time spent for each object, with the
nose of the mouse directed to and located within 2 cm from the
object or with the anterior limbs touching the object. In a first trial
(T1: 5 min) two similar objects (left and right: circle) were placed in
a symmetrical position 5 cm away from the wall. In a second trial
(T2: 5 min), two plastic dissimilar objects [one with a circle (left) and
a new one triangle (right)] were presented. The number of account
exploring each object during T1 and T2 was recorded. All mice
were tested 1 hr between T1 and T2.
Y-maze task
Recording the spontaneous alteration behavior in Y-maze was
assessed as spatial reference memory task. The apparatus consisted
of three identical arms (50 l616 w632 h cm) made by black
Plexiglas. Each mouse was placed at the end of one fixed arm and
allowed to move freely through the maze during an 8 min session.
The sequence of arm entries was recorded manually. An
alternation was defined as entries into all three arms on
consecutive choices. The number of maximum alternations was
then the total number of arms entered minus two, and the
percentage of alternation was calculated as (actual alternations/
maximum alternations) 6100. In addition, the total number of
arms entered during the session was also determined.
Measurements of monoamine neurotransmitters and
metabolites
Each mouse (male, 10–20 weeks old) was decapitated under
deep anesthesia and its brain quickly removed from the skull,
briefly washed in ice-cold saline, and laid on a cooled (4uC) metal
plate, on which it was rapidly dissected to separate the prefrontal
cortex, striatum, cerebellum, and thalamus. The dissected brain
regions were weighed, frozen, and stored at 280uC until analysis.
The regional levels of monoamines and their metabolites were
determined using a high-performance liquid chromatography
(HPLC) system equipped with an electrochemical detector
(HPLC-ECD System; Eicom, Kyoto, Japan). The HPLC system
and conditions were as follows: Eicom EP-300/Eicom ECD-300
system; column, Eicompak SC-5ODS (3.0 mm i.d.615 cm) with
precolumn; mobile phase, 83% 0.1 M citric acid/0.1 M sodium
acetate buffer, 17% methanol, 0.18% sodium 1-octanesulfonate,
containing 5 mg/ml disodium-EDTA; flow rate, 0.5 ml/min;
electrode, Eicom WE-3G graphite electrode; reference electrode,
Eicom RE-100 Ag/Ag Cl; applied voltage, 750 mV versus Ag/Ag
Cl. Column temperature was maintained at 25uC.
Morphological analysis
Mice were anesthetized with pentobarbital and perfused via the
ascending aorta with phosphate-buffered saline (PBS; pH 7.4)
until the outflow became clear, followed by 0.1 M phosphate
buffer (PB; pH 7.4) containing 4% paraformaldehyde (PFA) for
15 min. Brains were removed and postfixed in the same fixative
for 24 h at 4uC. The brain was sliced at 150 mm thickness using a
vibratome (Dosaka EM Co. Ltd, Kyoto, Japan). The slices were
transferred into a Silgard-coated Petri dish filled with 49,6 -
diamidino-2-phenylindole (DAPI) solution (1 mg/ml; Sigma, St.
Louis, MO) in PBS. Neurons in the infralimbic (IL) and prelimbic
(PL) regions of the medial prefrontal cortex (mPFC) were
penetrated with glass microelectrodes filled with 3% LY (lithium
salt; Sigma) in distilled water, and LY was injected by passing 2–
20 nA current with 2.5 second pulses applied at 0.2 Hz for 1–2
minutes. After LY injections, sections were postfixed in the same
fixative for 1–2 days, and then were incubated as follows: several
washes in PBS, 1 h in 0.1 M PBS containing with 1% BSA, 0.3%
TritonX-100 and 0.1% NaN3 (blocking solution); and with a
rabbit anti-LY polyclonal antibody (1:5000, Molecular probes) in
blocking solution at 4uC for 4–5 days. After washing, sections were
incubated for 3 h with Alexa 488-labeled anti-rabbit IgG (1:500,
Molecular probes). After several washes in PBS, sections were
mounted on slides with Vectashield (Vector Laboratory). Immu-
nofluorescent images were analyzed using a confocal laser
scanning microscope (Leica TCS). Pyramidal neurons within the
infralimbic and prelimbic regions were defined by the presence of
a single apical dendrite. For analyses of branching, basal dendrites
were evaluated by counting the number of branches on each
dendrite. Data were expressed as the mean number of branches
per dendrite. The average spine density (number of spines per
10 mm of dendritic length) was estimated on the first segments of
apical dendrites. For analyses of spine density and spine length,
spines were identified on the basis of the morphological criteria for
‘mushroom’ and ‘thin’ spines described by Peters and Kaiserman-
Abramof [55], with the only protrusions counted being those
perpendicular to the dendritic shaft and possessing a clear neck
and bulbous head. Spine length represents the radial distance from
the tip of the spine head to the dendritic shaft. These
morphological analyses were performed using 6 to 8 neurons
each from five controls and HB-EGF KO mice.
Immunoblotting analysis
Immunoblotting analyses of the prefrontal cortex region were
performed using male, 10-week-old animals (controls and KO mice).
Extracts prepared from the medial prefrontal cortex region were
treated with Laemmli’s sample solution and boiled for 3 min.
Samples containing equivalent amounts of protein were separated on
10% sodium dodecyl sulfatepolyacrylamide gels and transferred for
2 hr at 70 V to a polyvinylidene difluoride membrane using the
method of Towbin et al [56]. Membranes were then incubated for
1 hr in blocking solution containing 4% dry milk in T-TBS (20 mM
Tris-HCl, pH 7.5, 150 mM NaCl, and 0.1% Tween 20) at room
temperature and then incubated overnight at 4uC with antibodies
against PSD-95 (1:250, Transduction Laboratories, Lexington, KY,
U S A ) ,N R 1 ,N R 2 A( 1 : 1 0 0 0 ,U p s t a t eB i o t e c h n o l o g y ,L a k eP l a c i d ,
NY, USA), Nr2B (R&D Systems, Minneapolis, MN, USA), EGF
receptor, ErbB4 (1:1000, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), phospho-CaMKII (p-Thr286/p-Thr287) (1:5000), anti-
CaMKII (1:5000),b-tubulin (1:5000) ERK, p-ERK, AKT, p-AKT,
PLCc,p - P L C c, phospho-PAK1 (Thr423), phospho-PAK2 (Thr402),
or phospho-PAK3 (Thr421) (1:1000, Cell Signaling Technology,
Beverly, MA, USA) in blocking solution. After washing in T-TBS,
membranes were incubated with horseradish peroxidase-conjugated
anti-mouse or anti-rabbit IgG to visualize primary antibodies using
enhanced chemiluminescence plus western blotting detection reagent
(Amersham Pharmacia Biotech, Amersham, UK), according to the
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semi-quantitatively using NIH Image (Research Services Branch of
the National Institute of Mental Health). Optical densities of
corresponding immunoreactive bands were obtained by subtraction
of the background density within the same image.
Autophosphorylation of ErbB receptor in HB-EGF KO
mice
Immunoblotting analyses of the autophosphorylation of the
ErbB receptor were performed using the prefrontal cortex region.
In this study, membrane protein was extracted using a Native
Membrane Protein Extraction Kit (Calbiochem, Cambridge, MA,
USA) according to the manufacturer’s instructions. Then,
membrane protein was immunoblotted using an anti-phospho-
EGF receptor antibody and an anti-phospho-ErbB4 antibody
(1:1000, Cell Signaling Technology), as described above.
Statistical analysis
All data were expressed as the mean6SEM. Statistical
significant was evaluated either by either one-way or two-way
ANOVA test followed by a post hoc Dunnett’s test. A P-value of
,0.05 was considered to be statistically significant.
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